Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Objectives:
1. To determine the relative toxicities, engraftment potential, kinetics of engraftment,
degree of chimerism and disease control achieved with the combination of fludarabine and
busulfan at different dose levels and different dose schedules in patients undergoing
allogeneic stem cell transplant (SCT).
2. Determine pharmacokinetics, and toxicity of intravenous busulfan given at equal total
dose levels given four times daily, or once daily.
3. In vivo determination of fludarabine inhibitory effects on DNA repair.